<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-242-10-116-121</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-3254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Воспалительные маркеры и маркеры эндотелиальной дисфункции у пациентов с воспалительными заболеваниями кишечника</article-title><trans-title-group xml:lang="en"><trans-title>Inflammatory markers and endothelial dysfunction markers in patients with inflammatory bowel disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1496-0689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasova</surname><given-names>L. V.</given-names></name></name-alternatives><email xlink:type="simple">tlarisagast18@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4534-999X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаев</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaev</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8339-9496</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsyganova</surname><given-names>Yu. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Чувашский государственный университет имени И.Н. Ульянова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chuvash State University n.a. I.N. Ulyanov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>01</month><year>2026</year></pub-date><volume>0</volume><issue>10</issue><fpage>116</fpage><lpage>121</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тарасова Л.В., Николаев А.А., Цыганова Ю.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Тарасова Л.В., Николаев А.А., Цыганова Ю.В.</copyright-holder><copyright-holder xml:lang="en">Tarasova L.V., Nikolaev A.A., Tsyganova Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/3254">https://www.nogr.org/jour/article/view/3254</self-uri><abstract><p>У пациентов с ВЗК наиболее чувствительными маркерами ЭД являются VCAM-1, ICAM-1 и vWF, показатели которых повышены в активной фазе и снижаются при ремиссии. СРБ демонстрирует устойчивую корреляцию с активностью болезни Крона, но менее предсказуем при язвенном колите. Уровни ET-1 при ВЗК остаются относительно неизменными, однако при экспериментальных моделях колита и при хроническом увеите наблюдаются изменения. ADMA демонстрирует неоднозначные результаты при ВЗК, но повышен при изолированных проявлениях увеита, указывая на системное воспаление даже при клинически локализованных поражениях.</p></abstract><trans-abstract xml:lang="en"><p>In patients with IBD the most sensitive markers of ED are VCAM-1, ICAM-1 and vWF, whose levels increase during the active phase and decrease during remission. CRP shows a stable correlation with Crohn’s disease activity, but is less predictive in ulcerative colitis. Levels of ET-1 in IBD remain relatively unchanged; however, changes are observed in experimental models of colitis and in chronic uveitis. ADMA shows ambiguous results in IBD but is elevated in isolated uveitis manifestations, indicating systemic inflammation even in clinically localized lesions.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелиальная дисфункция</kwd><kwd>воспалительные заболевания кишечника</kwd><kwd>VCAM-1</kwd><kwd>ICAM-1</kwd><kwd>ADMA</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial dysfunction</kwd><kwd>inflammatory bowel disease</kwd><kwd>VCAM-1</kwd><kwd>ICAM-1</kwd><kwd>ADMA</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical guidelines. Ulcerative colitis. K51. 2024. All-Russian public organization "Association of Coloproctologists of Russia", Russian Gastroenterological Association.@@ Клинические рекомендации. Язвенный колит. K51. 2024. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская Гастроэнтерологическая Ассоциация.</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines. Ulcerative colitis. K51. 2024. All-Russian public organization "Association of Coloproctologists of Russia", Russian Gastroenterological Association.@@ Клинические рекомендации. Язвенный колит. K51. 2024. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская Гастроэнтерологическая Ассоциация.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical guidelines. Crohn's disease. K50. 2024. All-Russian public organization "Association of Coloproctologists of Russia", Russian Gastroenterological Association.@@ Клинические рекомендации. Болезнь Крона. K50. 2024. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская Гастроэнтерологическая Ассоциация.</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines. Crohn's disease. K50. 2024. All-Russian public organization "Association of Coloproctologists of Russia", Russian Gastroenterological Association.@@ Клинические рекомендации. Болезнь Крона. K50. 2024. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская Гастроэнтерологическая Ассоциация.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Badimon L, Pena E, Arderiu G, Padro T, Slevin M, Vilahur G, et al. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 2018;9:430. doi:10.3389/fimmu.2018.00430</mixed-citation><mixed-citation xml:lang="en">Badimon L, Pena E, Arderiu G, Padro T, Slevin M, Vilahur G, et al. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 2018;9:430. doi:10.3389/fimmu.2018.00430</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009 Sep;206(1):61-8. doi:10.1016/j.atherosclerosis.2009.02.002.</mixed-citation><mixed-citation xml:lang="en">Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009 Sep;206(1):61-8. doi:10.1016/j.atherosclerosis.2009.02.002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68(2):357-418. doi:10.1124/pr.115.011833</mixed-citation><mixed-citation xml:lang="en">Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68(2):357-418. doi:10.1124/pr.115.011833</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Banecki KMRM, Dora KA. Endothelin-1 in Health and Disease.Int J Mol Sci. 2023;24:11295. doi:10.3390/ijms241411295</mixed-citation><mixed-citation xml:lang="en">Banecki KMRM, Dora KA. Endothelin-1 in Health and Disease.Int J Mol Sci. 2023;24:11295. doi:10.3390/ijms241411295</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Haydinger CD, Ashander LM, Tan ACR, Smith JR.Intercellular Adhesion Molecule 1: More than a Leukocyte Adhesion Molecule. Biology. 2023;12:743. doi:10.3390/biology12050743</mixed-citation><mixed-citation xml:lang="en">Haydinger CD, Ashander LM, Tan ACR, Smith JR.Intercellular Adhesion Molecule 1: More than a Leukocyte Adhesion Molecule. Biology. 2023;12:743. doi:10.3390/biology12050743</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Furuta K, Guo Q, Pavelko KD, Lee JH, Robertson KD, Nakao Y, et al. Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. J Clin Invest. 2021 Mar 15;131(6): e143690. doi:10.1172/JCI143690. PMID:33476308; PMCID: PMC7954604</mixed-citation><mixed-citation xml:lang="en">Furuta K, Guo Q, Pavelko KD, Lee JH, Robertson KD, Nakao Y, et al. Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. J Clin Invest. 2021 Mar 15;131(6): e143690. doi:10.1172/JCI143690. PMID:33476308; PMCID: PMC7954604</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001 May;107(10):1209-10. doi:10.1172/JCI13005.</mixed-citation><mixed-citation xml:lang="en">Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001 May;107(10):1209-10. doi:10.1172/JCI13005.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1183586. doi:10.3389/fendo.2023.1183586</mixed-citation><mixed-citation xml:lang="en">Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1183586. doi:10.3389/fendo.2023.1183586</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Huang SS, Huang WC, Tsai CT, et al. Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease. Sci Rep. 2023;13:7541. doi:10.1038/s41598-023-32728-9</mixed-citation><mixed-citation xml:lang="en">Huang SS, Huang WC, Tsai CT, et al. Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease. Sci Rep. 2023;13:7541. doi:10.1038/s41598-023-32728-9</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jones SC, Banks RE, Haidar A, Gearing AJ, Hemingway IK, Ibbotson SH, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995 May;36(5):724-30. doi:10.1136/gut.36.5.724.</mixed-citation><mixed-citation xml:lang="en">Jones SC, Banks RE, Haidar A, Gearing AJ, Hemingway IK, Ibbotson SH, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995 May;36(5):724-30. doi:10.1136/gut.36.5.724.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen OH, Brynskov J, Vainer B. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Dig Dis Sci. 1996 Sep;41(9):1780-5. doi:10.1007/BF02088745.</mixed-citation><mixed-citation xml:lang="en">Nielsen OH, Brynskov J, Vainer B. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Dig Dis Sci. 1996 Sep;41(9):1780-5. doi:10.1007/BF02088745.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gu P, Theiss A, Han J, Feagins LA. Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease. J Clin Gastroenterol. 2017 Jul;51(6):522-527. doi:10.1097/MCG.0000000000000618.</mixed-citation><mixed-citation xml:lang="en">Gu P, Theiss A, Han J, Feagins LA. Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease. J Clin Gastroenterol. 2017 Jul;51(6):522-527. doi:10.1097/MCG.0000000000000618.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Soriano A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000 Oct;80(10):1541-51. doi:10.1038/labinvest.3780164.</mixed-citation><mixed-citation xml:lang="en">Soriano A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000 Oct;80(10):1541-51. doi:10.1038/labinvest.3780164.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cartland R, Burns R, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121(6):1428-1436</mixed-citation><mixed-citation xml:lang="en">Cartland R, Burns R, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121(6):1428-1436</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cibor D, Owczarek D, Butenas S, Salapa K, Mach T, Undas A. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. World J Gastroenterol. 2017 Jul 14;23(26):4796-4805. doi:10.3748/wjg.v23.i26.4796.</mixed-citation><mixed-citation xml:lang="en">Cibor D, Owczarek D, Butenas S, Salapa K, Mach T, Undas A. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. World J Gastroenterol. 2017 Jul 14;23(26):4796-4805. doi:10.3748/wjg.v23.i26.4796.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Meucci G, Pareti F, Vecchi M, Saibeni S, Bressi C, de Franchis R. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol. 1999 Mar;34(3):287-90. doi:10.1080/00365529950173708.</mixed-citation><mixed-citation xml:lang="en">Meucci G, Pareti F, Vecchi M, Saibeni S, Bressi C, de Franchis R. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol. 1999 Mar;34(3):287-90. doi:10.1080/00365529950173708.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McCartney SA, Ballinger AB, Vojnovic I, Farthing MJ, Warner TD. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci. 2002 Sep 6;71(16):1893-904. doi:10.1016/s0024-3205(02)01923-9.</mixed-citation><mixed-citation xml:lang="en">McCartney SA, Ballinger AB, Vojnovic I, Farthing MJ, Warner TD. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci. 2002 Sep 6;71(16):1893-904. doi:10.1016/s0024-3205(02)01923-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Korkmaz H, Asıl M, Temel T, Öztürk B, Kebapçılar L. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases. Turk J Med Sci. 2021 Oct 21;51(5):2403-2412. doi:10.3906/sag-2103-220. PMID:33984894</mixed-citation><mixed-citation xml:lang="en">Korkmaz H, Asıl M, Temel T, Öztürk B, Kebapçılar L. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases. Turk J Med Sci. 2021 Oct 21;51(5):2403-2412. doi:10.3906/sag-2103-220. PMID:33984894</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010 Jan;16(1):52-7. doi:10.1002/ibd.20994.</mixed-citation><mixed-citation xml:lang="en">Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010 Jan;16(1):52-7. doi:10.1002/ibd.20994.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in inflammatory bowel disease: a practical guide. Therap Adv Gastroenterol. 2024 May 9;17:17562848241251600. doi:10.1177/17562848241251600. PMID:38737913; PMCID: PMC11085009</mixed-citation><mixed-citation xml:lang="en">Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in inflammatory bowel disease: a practical guide. Therap Adv Gastroenterol. 2024 May 9;17:17562848241251600. doi:10.1177/17562848241251600. PMID:38737913; PMCID: PMC11085009</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M, et al. Evaluation of the modified Crohn’s disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. Medicine (Baltimore). 2021 Feb 12;100(6): e24717. doi:10.1097/MD.0000000000024717</mixed-citation><mixed-citation xml:lang="en">Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M, et al. Evaluation of the modified Crohn’s disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. Medicine (Baltimore). 2021 Feb 12;100(6): e24717. doi:10.1097/MD.0000000000024717</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Peyrin-Biroulet L, Reinisch W, Colombel J, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88-95</mixed-citation><mixed-citation xml:lang="en">Peyrin-Biroulet L, Reinisch W, Colombel J, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88-95</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Koczka C, Goodman A, Abramowitz M, Jain P. Are Inflammatory Markers Predictive of Length of Hospital Stay in Patients with Inflammatory Bowel Disease?: 1162. Am J Gastroenterol. 2010;105(Suppl): S421</mixed-citation><mixed-citation xml:lang="en">Koczka C, Goodman A, Abramowitz M, Jain P. Are Inflammatory Markers Predictive of Length of Hospital Stay in Patients with Inflammatory Bowel Disease?: 1162. Am J Gastroenterol. 2010;105(Suppl): S421</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Guclu H, Gurlu V.Comparison of corneal endothelial cell analysis in patients with uveitis and healthy subjects.Int Ophthalmol. 2019;39. doi:10.1007/s10792-017-0809-7</mixed-citation><mixed-citation xml:lang="en">Guclu H, Gurlu V.Comparison of corneal endothelial cell analysis in patients with uveitis and healthy subjects.Int Ophthalmol. 2019;39. doi:10.1007/s10792-017-0809-7</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sayed O, Abdel-Magied R, Elela M, Abdel-Nasser A. Value of Serum Asymmetric Dimethylarginine (ADMA) As a Novel Biomarker for Uveitis in Behçet’s Disease. Ocul Immunol Inflamm. 2024;33:1-7. doi:10.1080/09273948.2024.2342378</mixed-citation><mixed-citation xml:lang="en">Sayed O, Abdel-Magied R, Elela M, Abdel-Nasser A. Value of Serum Asymmetric Dimethylarginine (ADMA) As a Novel Biomarker for Uveitis in Behçet’s Disease. Ocul Immunol Inflamm. 2024;33:1-7. doi:10.1080/09273948.2024.2342378</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Klok AM, Luyendijk L, Zaal MJ, Rothova A, Kijlstra A. Soluble ICAM-1 serum levels in patients with intermediate uveitis. Br J Ophthalmol. 1999 Jul;83(7):847-51. doi:10.1136/bjo.83.7.847.</mixed-citation><mixed-citation xml:lang="en">Klok AM, Luyendijk L, Zaal MJ, Rothova A, Kijlstra A. Soluble ICAM-1 serum levels in patients with intermediate uveitis. Br J Ophthalmol. 1999 Jul;83(7):847-51. doi:10.1136/bjo.83.7.847.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Powierza K, Sawicka-Powierza J, Urban B, Żelazowska-Rutkowska B, Cylwik B, Mikołuć B, et al. Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis. Clin Ophthalmol. 2021 Jan 12;15:157-164. doi:10.2147/OPTH.S276109.</mixed-citation><mixed-citation xml:lang="en">Powierza K, Sawicka-Powierza J, Urban B, Żelazowska-Rutkowska B, Cylwik B, Mikołuć B, et al. Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis. Clin Ophthalmol. 2021 Jan 12;15:157-164. doi:10.2147/OPTH.S276109.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
